Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022

Changes in testing behaviors and reporting requirements have hampered the ability to estimate the U.S. SARS-CoV-2 incidence (1). Hybrid immunity (immunity derived from both previous infection and vaccination) has been reported to provide better protection than that from infection or vaccination alone (2). To estimate the incidence of infection and the prevalence of infection- or vaccination-induced antibodies (or both), data from a nationwide, longitudinal cohort of blood donors were analyzed. During the second quarter of 2021 (April–June), an estimated 68.4% of persons aged ≥16 years had infection- or vaccination-induced SARS-CoV-2 antibodies, including 47.5% from vaccination alone, 12.0% from infection alone, and 8.9% from both. By the third quarter of 2022 (July–September), 96.4% had SARS-CoV-2 antibodies from previous infection or vaccination, including 22.6% from infection alone and 26.1% from vaccination alone; 47.7% had hybrid immunity. Prevalence of hybrid immunity was lowest among persons aged ≥65 years (36.9%), the group with the highest risk for severe disease if infected, and was highest among those aged 16–29 years (59.6%). Low prevalence of infection-induced and hybrid immunity among older adults reflects the success of public health infection prevention efforts while also highlighting the importance of older adults staying up to date with recommended COVID-19 vaccination, including at least 1 bivalent dose.*^,†

Since July 2020, SARS-CoV-2 seroprevalence in the United States has been estimated by testing blood donations (3). CDC, in collaboration with Vitalant, American Red Cross, Creative Testing Solutions, and Westat, established a nationwide cohort of 142,758 blood donors in July 2021; the cohort included persons who had donated blood two or more times in the preceding year.^§ All blood donations collected during April–June 2021 were tested for antibodies against the spike (S) and nucleocapsid (N) proteins. Beginning in 2022, up to one blood donation sample per donor was randomly selected each quarter and tested using the Ortho VITROS SARS-CoV-2 Quantitative S immunoglobulin G^¶ and total N antibody** tests. Both SARS-CoV-2 infection and COVID-19 vaccination result in production of anti-S antibodies, whereas anti-N antibodies only result from infection. At each donation, blood donors were asked if they had received a COVID-19 vaccine. Using vaccination history and results of antibody testing, the prevalence of the U.S. population aged ≥16 years with vaccine-induced, infection-induced, or hybrid immunity was estimated for four 3-month periods (April–June 2021, January–March 2022, April–June 2022, and July–September 2022); in addition, the proportion of persons who transitioned from one immune status to another by quarter was estimated. Analysis was limited to 72,748 (51.0%) donors for whom it was possible to ascertain immune status during each period using their prior classification (e.g., previously infected or vaccinated), antibody testing results, and their vaccination status at the time of each donation.^†† The sample data were weighted to account for selection into the study cohort, for nonresponse during the four analysis periods, and for demographic differences between the blood donor population and the overall U.S. population. The weights were obtained through a combination of stratification and raking, an iterative weighting adjustment procedure (4). Rates of infection among those previously uninfected were estimated for each period by determining the percentage of anti-N–negative persons seroconverting to anti-N–positive from one 3-month period included in the study to the next. Estimates were stratified by age group (16–29, 30–49, 50–64, and ≥65 years) and race and ethnicity^§§ (Asian, Black or African American [Black], White, Hispanic or Latino [Hispanic], and other). SAS (version 9.4; SAS Institute) was used to compute the final weights, and R (version 4.2.1; R Foundation) was used to calculate all the estimates and create the plots.^¶¶ Seroprevalence and infection rates were estimated as weighted means and compared by demographic group and vaccination status using two-sided t-tests with a significance level of α = 0.05. This activity was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.***

During the first quarter examined (April–June 2021), an estimated 68.4% (95% CI = 67.8%–68.9%) of persons aged ≥16 years had SARS-CoV-2 antibodies from previous infection or vaccination, including 47.5% (95% CI = 46.0%–49.0%) from vaccination alone, 12.0% (95% CI = 10.8%–13.5%) from infection alone, and 8.9% (95% CI = 8.7%–9.2%) from both (Figure 1) (Supplementary Figure 1, https://stacks.cdc.gov/view/cdc/128630). During January–March 2022, 93.5% (95% CI = 93.1%–93.9%) of persons aged ≥16 years had antibodies from previous infection or vaccination, including 39.0% (95% CI = 37.4%–40.7%) from vaccination alone, 20.5% (95% CI = 19.2%–22.2%) from infection alone, and 34.1% (95% CI = 32.4%–35.8%) from both. During July–September 2022, 96.4% (95% CI = 96.1%–96.7%) of persons had antibodies from previous infection or vaccination, including 26.1% (95% CI = 25.4%–26.9%) with vaccine-induced immunity alone, 22.6% (95% CI = 21.2%–24.1%) with infection-induced immunity alone, and 47.7% (95% CI = 44.8%–51.2%) with hybrid immunity. During July–September 2022, the prevalence of infection-induced immunity was 85.7% (95% CI = 79.8%–90.2%) among unvaccinated persons and 64.3% (95% CI = 61.9%–66.7%) among vaccinated persons.

During July–September 2022, the lowest prevalence of hybrid immunity, 36.9% (95% CI = 35.8%–38.1%), was observed in persons aged ≥65 years, and the highest, 59.6% (95% CI = 56.7%–62.3%), in adolescents and young adults aged 16–29 years (Figure 2) (Supplementary Figure 2, https://stacks.cdc.gov/view/cdc/128679). During all periods, higher prevalences of hybrid immunity were observed among Black and Hispanic populations than among White and Asian populations (Supplementary Figure 3, https://stacks.cdc.gov/view/cdc/128680).

Among persons with no previous infection, the incidence of first infections during the study period (i.e., conversion from anti-N–negative to anti-N–positive) was higher among unvaccinated persons (Table). From April–June 2021 through January–March 2022, the incidence of first SARS-CoV-2 infections among unvaccinated persons was 67.0%, compared with 26.3% among vaccinated persons (p<0.05). From January–March 2022 through April–June 2022, the incidence among unvaccinated persons was 21.7% and was 13.3% among vaccinated persons. Between April–June 2022 and July–September 2022, the incidence among unvaccinated persons was 28.3%, compared with 22.9% among vaccinated persons (p<0.05). Incidence of first SARS-CoV-2 infections was higher among younger than among older persons and was lower among Asian persons than among other racial and ethnic populations, but the differences among groups narrowed over time.

Acknowledgments

Brad Biggerstaff, Matthew McCullough, CDC; Roberta Bruhn, Brian Custer, Xu Deng, Zhanna Kaidarova, Kathleen Kelly, Anh Nguyen, Graham Simmons, Hasan Sulaeman, Elaine Yu, Karla Zurita-Gutierrez, Vitalant Research Institute; Akintunde Akinseye, Jewel Bernard-Hunte, Robyn Ferg, Rebecca Fink, Caitlyn Floyd, Isaac Lartey, Sunitha Mathews, David Wright, Westat; Jamel Groves, James Haynes, David Krysztof, American Red Cross; Ralph Vassallo, Vitalant; Sherri Cyrus, Phillip Williamson, Creative Testing Solutions; Paul Contestable, QuidelOrtho; Steve Kleinman, University of British Columbia; CDC, Vitalant Research Institute, Westat, American Red Cross, and Creative Testing Solutions staff members; blood donors whose samples were analyzed and who responded to surveys for this study.

Corresponding author: Jefferson M. Jones, [email protected].

¹National Center for Immunization and Respiratory Diseases, CDC; ²Westat, Rockville, Maryland; ³Vitalant Research Institute, San Francisco, California; ⁴American Red Cross, Washington, DC; ⁵Creative Testing Solutions, Tempe, Arizona.

References

1. Rader B, Gertz A, Iuliano AD, et al. Use of at-home COVID-19 tests—United States, August 23, 2021–March 12, 2022. MMWR Morb Mortal Wkly Rep 2022;71:489–94. https://doi.org/10.15585/mmwr.mm7113e1 PMID:35358168
2. Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the Omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis 2023;23:556–67. https://doi.org/10.1016/S1473-3099(22)00801-5 PMID:36681084
3. Jones JM, Stone M, Sulaeman H, et al. Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020–May 2021. JAMA 2021;326:1400–9. https://doi.org/10.1001/jama.2021.15161 PMID:34473201
4. Deville J-C, Särndal C-E, Sautory O. Generalized raking procedures in survey sampling. J Am Stat Assoc 1993;88:1013–20. https://doi.org/10.1080/01621459.1993.10476369
5. Steele MK, Couture A, Reed C, et al. Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. JAMA Netw Open 2022;5:e2220385. https://doi.org/10.1001/jamanetworkopen.2022.20385 PMID:35793085
6. Higdon MM, Wahl B, Jones CB, et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect Dis 2022;9:ofac138. https://doi.org/10.1093/ofid/ofac138 PMID:35611346
7. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022;399:924–44. https://doi.org/10.1016/S0140-6736(22)00152-0 PMID:35202601
8. Thorpe A, Fagerlin A, Drews FA, Shoemaker H, Scherer LD. Self-reported health behaviors and risk perceptions following the COVID-19 vaccination rollout in the USA: an online survey study. Public Health 2022;208:68–71. https://doi.org/10.1016/j.puhe.2022.05.007 PMID:35717747
9. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev 2022;310:27–46. https://doi.org/10.1111/imr.13089 PMID:35733376
10. Atti A, Insalata F, Carr EJ, et al.; SIREN Study Group and the Crick COVID Immunity Pipeline Consortium. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study. J Infect 2022;85:545–56. https://doi.org/10.1016/j.jinf.2022.09.004 PMID:36089104

FIGURE 1. Prevalences of vaccine-induced, infection-induced, and hybrid* immunity^† against SARS-CoV-2 among blood donors aged ≥16 years — United States, April 2021–September 2022

* Immunity derived from a combination of vaccination and infection.

^† Ascertained by the presence of anti-spike antibodies (present in both COVID-19–vaccinated and SARS-CoV-2–infected persons) and anti-nucleocapsid antibodies (present only in previously infected persons) and self-reported history of vaccination.

FIGURE 2. Prevalences of vaccine-induced, infection-induced, and hybrid* immunity^† against SARS-CoV-2 among blood donors aged ≥16 years, by age group — United States, April 2021–September 2022

* Immunity derived from a combination of vaccination and infection.

^† Ascertained by the presence of anti-spike antibodies (present in both COVID-19–vaccinated and SARS-CoV-2–infected persons) and anti-nucleocapsid antibodies (present only in previously infected persons) and self-reported history of vaccination.

* Percentage of uninfected persons (anti-nucleocapsid–negative in the previous 3-month period) seroconverting to anti-nucleocapsid–positive. If both vaccination and infection occurred between donations included in the study, the order could not be determined, and some unvaccinated donors might have been vaccinated before infection and thus misclassified.
^† If donors who transitioned from no antibodies to hybrid immunity between April–June 2021 and January–March 2022 were excluded, an estimated 55.5% (95% CI = 53.9%–57.1%) of unvaccinated donors were infected. For other periods, exclusion did not substantially change results. Between January–March and April–June 2022, 0.4% of persons shifted from no antibodies to hybrid immunity. Between April–June and July–September 2022, 0.3% of persons shifted from no antibodies to hybrid immunity.
^§ Persons of Hispanic or Latino (Hispanic) origin might be of any race but are categorized as Hispanic; all racial groups are non-Hispanic.
^¶ Includes American Indian or Alaska Native and non-Hispanic persons of other races.